Alnylam CEO John Maraganore is stepping down at the end of the year, having taken the company from concept to commercial stage over nearly 20 years. The news overshadowed other updates during Alnylam Pharmaceuticals Inc.’s third quarter 2021 earnings call on 28 October.
The biotech also reported a solid growth quarter for its three-product commercial portfolio and positive 18-month data for what the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?